Immunotherapy has emerged as a promising strategy against cancer, but many patients fail to achieve durable responses. Inefficiency of immunotherapy is often caused by the immunosuppressive tumor ...

Re-escalation of anti-TNF therapy is common among older adults with RA and typically occurs within 6 months of prior de-escalation.

TNF Pharmaceuticals, Inc. (TNFA) announced on Wednesday that it has changed its corporate name to Q/C Technologies and will begin trading under a new ticker on the Nasdaq Capital Market starting ...

Gastrointestinal dysfunction often precedes motor symptoms in Parkinson’s disease (PD), suggesting the enteric nervous system (ENS) is central to early pathogenesis. How α-synuclein contributes to ENS ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the “Company”), a clinical stage biopharmaceutical company committed to developing novel ...

Tumor necrosis factor (TNF) inhibitors protect patients with axial spondyloarthritis (axSpA) from hip and spine fractures better than other drugs. Large US insurance claims database study comparing ...

Starting anti-TNF treatment at diagnosis is more cost-effective than accelerated step-up care for active Crohn’s disease, saving £1681 per patient over 5 years while improving clinical outcomes by ...

Shares of TNF Pharmaceuticals, Inc. (TNFA) traded nearly 5% higher on Tuesday afternoon after it announced a partnership with Renova Health for the application of AI and machine learning technologies ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune ...

Are you ready for some football? The Houston Texans host the Buffalo Bills on tonight’s edition of Thursday Night Football! It’s been a wild past few games for the Bills (7-3). Buffalo recently ...